Juno is an integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer, having developed cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Following Bristol-Myers Squibb's completion of its acquisition of Celgene in November 2019, Juno has been integrated into BMS's oncology and cell therapy portfolio, positioning it to leverage the parent company's scale and resources.
Cyborg Score Rationale
Juno benefits from BMS ownership, which provides robust R&D funding and clinical infrastructure. 2026 is expected to be a big pipeline year for Bristol Myers, with seven pivotal trials expected to read out for experimental drugs, creating near-term value inflection potential. However, as a fully-owned subsidiary without independent market access, execution risk is tied entirely to parent company strategy.
Top Insights
Acquired by Bristol Myers Squibb in 2020 (via Celgene) for approximately $9 billion, Juno's integration into BMS has significantly influenced the competitive dynamics within the rapidly evolving biotech landscape, particularly in the CAR-T and next-generation immunotherapies sector
Seven pivotal trials are expected to read out in 2026 for experimental drugs under Bristol Myers, providing near-term catalysts for Juno's pipeline advancement
In June 2025, Bristol Myers Squibb transferred Juno Therapeutics GmbH to TQ Therapeutics GmbH through a share acquisition agreement intended to accelerate the development of innovative cell therapies
Juno operates as BMS's core CAR-T and advanced cell therapy platform, supporting the parent company's oncology franchise and addressing unmet needs in hematologic and solid tumors
Named Competitors
Yescarta — CAR-T cell therapy for lymphomas
Kymriah — CAR-T cell therapy for hematologic malignancies
Breyanzi — Approved CAR-T therapy for relapsed/refractory lymphoma
Tecartus — CAR-T therapy for mantle cell lymphoma
Recent Developments
(June 2025) Transfer of Juno Therapeutics GmbH German subsidiary to TQ Therapeutics to accelerate cell therapy development
(April 2025) Raised $129 million in funding to expand research infrastructure and clinical trial capabilities
(2026) Seven pivotal trials expected to read out across Bristol Myers pipeline, including CAR-T programs from Juno portfolio
Open the full interactive Juno Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.